Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DFY5L8
|
|||
| Drug Name |
Afamitresgene autoleucel
|
|||
| Synonyms |
afami-cel
Click to Show/Hide
|
|||
| Drug Type |
CAR-T cell therapy
|
|||
| Indication | Soft tissue sarcoma [ICD-11: 2B57; ICD-9: 171] | Phase 2 | [1] | |
| Company |
Adaptimmune Philadelphia, PA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Melanoma-associated antigen 4 (MAGEA4) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04044768) A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR? T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma. U.S.National Institutes of Health. | |||
| REF 2 | Autologous T cell therapy for MAGE-A4(+) solid cancers in HLA-A*02(+) patients: a phase 1 trial. Nat Med. 2023 Jan;29(1):104-114. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.